- Record: found
- Abstract: not found
- Article: not found
RAMOSE: an open-label randomized phase II study of osimertinib with or without ramucirumab in TKI-naive EGFR-mutant metastatic NSCLC
Read this article at
ScienceOpen
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.